Latest news and updates
Georgia Ryan White Part B/ADAP Adds Hepatitis C Medications to Formulary
In order to combat transmission and decrease the number of existing cases of Hepatitis C Viral (HCV) infection, the Georgia Ryan White Part B/ADAP has added seven (7) Hepatitis C medications to the ADAP formulary. These medications include Daklinza (Daclatasvir), Harvoni (Ledipasvir/Sofosbuvir), Ribavirin, Sovaldi (Sofosbuvir), Technivie (Ombitasvir/Paritaprevir/Ritonavir), Viekira Pak (Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir), and Zepatier.
The Georgia Ryan White Part B/ADAP will be tracking the utilization, and administration of these medications to eligible, dually infected patients to determine the sustainability of the regimens for the ADAP program as payer of last resort. These new HCV medications will be available to ADAP eligible clients after completion of a required prior approval form. Eligible clients must be currently enrolled in ADAP and eligible for ADAP assistance for the full duration of treatment.
If you are HIV/HCV co-infected, please speak to your medical provider about your eligibility to receive Hepatitis C Medications through the ADAP program.
If there are any questions, please do not hesitate to call the Georgia ADAP/HICP Program Manager at 404-463-0416 or email at [email protected].